MedTrace Logo

Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)

NCT04734353 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 492

Last updated 2021-02-02

No results posted yet for this study

Summary

E5TION will evaluate the efficacy, safety and tolerability of tailored two regimens (prasugrel 5mg/d vs. ticagrelor 60mg bid) in high-risk patients undergoing PCI (CHIP: COmplex and Higher-Risk Indicated PCI/PatieNts).

Conditions

Interventions

DRUG

Prasugrel 5mg

Prasugrel 20 mg loading, followed by prasugrel 5 mg/day for 12 months

DRUG

Ticagrelor 60mg

Ticagrelor 120 mg loading, followed by ticagrelor 60 mg bid for 12 months

Sponsors & Collaborators

  • U&I Corporation

    collaborator OTHER

  • Gyeongsang National University Hospital

    lead OTHER

Principal Investigators

  • Young-Hoon Jeong, MD, PhD · Changwon Gyeongsang National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-15
Primary Completion
2021-06-15
Completion
2022-06-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04734353 on ClinicalTrials.gov